Terns Pharmaceuticals, Inc. (TERN)

In the past six months, Terns Pharmaceuticals experienced positive data for TERN-701 and Fast Track designation, an upsized public offering, discontinuation of the TERN-601 program, varied analyst ratings, Q2 2025 financial results, and a strategic shift to refocus on oncology.

As a clinical-stage biopharmaceutical company, Terns Pharmaceuticals, Inc. does not have commercialized products or services that are subject to traditional demand seasonality.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for oncology and obesity. Its pipeline includes TERN-701 for chronic myeloid leukemia (CML), TERN-501 for metabolic dysfunction-associated steatohepatitis (MASH) and obesity, TERN-601 (discontinued) for obesity, and TERN-800 series for obesity.

Terns Pharmaceuticals, Inc. is headquartered in Foster City, California, United States, and has a significant operational footprint in Shanghai, China.

Terns Pharmaceuticals has built its reputation on a capital-efficient drug discovery model. Its reputation has been influenced by positive clinical trial data, a strategic shift and program discontinuation, and analyst coverage.

Terns Pharmaceuticals, Inc. has significant institutional ownership, with 271 institutional owners holding 53% of the shares. The general public holds approximately 20.4% of the shares, while insider ownership is relatively low, under 1%.